Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890828211> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2890828211 abstract "e20512 Background: Veristrat (Biodesix, Boulder, CO) is a blood based proteomic assay that is dominated by inflammatory proteins and is prognostic and predictive in metastatic NSCLC after treatment with platinum based chemotherapy (Gregorc et al, Lancet 2014). Smoldering inflammation in the tumor microenvironment regulates and escalates cancer invasion, angiogenesis and immune surveillance escape (Balkwill and Mantovani, Lancet 2001). There is preclinical evidence to suggest that the tumor microenvironment can be altered with immunomodulatory interventions (Martino et al, 2016). While immune checkpoint blockade has shown durable benefit in metastatic NSCLC, the response rates still hover around 20%. As a result, identification of predictive biomarkers are of critical importance. The predictive value of the Veristrat assay with respect to ICB is poorly defined. Methods: At our institution, 83 pts with metastatic lung cancer pts were treated with nivolumab between 6/2015 to 12/2016. The following clinicopathologic characteristics were abstracted from medical records: tumor histology, Veristrat status, no. of doses of nivolumab, irAEs and overall survival. Results: Of the 83 pts, 65 pts were found to have NSCLC. Veristrat status was available for 17/65 of these pts. Nine pts were identified to have “Veristrat good” and seven pts were “Veristrat poor”. Median number of nivolumab doses was 4. Median survival for all patients was 30 weeks. Median survival was 20 weeks for “Veristrat poor” and 26 weeks for “Veristrat good”(p = 0.68). Grade 3-4 irAEs were noted in 5/9 patients with “Veristrat good” and 5/7 patients with “Veristrat poor”. Conclusions: “Veristrat poor” pts treated with ICB have a lower median survival as compared to “Veristrat good” pts. Our study did not meet statistically significant end point due to limited sample size. Further studies are needed to identify poorly immunogenic tumors and develop novel treatment approaches to optimize outcomes. [Table: see text]" @default.
- W2890828211 created "2018-09-27" @default.
- W2890828211 creator A5026029965 @default.
- W2890828211 creator A5039326252 @default.
- W2890828211 creator A5048644068 @default.
- W2890828211 creator A5057076335 @default.
- W2890828211 creator A5058009962 @default.
- W2890828211 creator A5061742224 @default.
- W2890828211 creator A5072140037 @default.
- W2890828211 creator A5080870567 @default.
- W2890828211 date "2017-05-20" @default.
- W2890828211 modified "2023-09-27" @default.
- W2890828211 title "Veristrat based stratification of responses to immune checkpoint blockade (ICB)." @default.
- W2890828211 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e20512" @default.
- W2890828211 hasPublicationYear "2017" @default.
- W2890828211 type Work @default.
- W2890828211 sameAs 2890828211 @default.
- W2890828211 citedByCount "0" @default.
- W2890828211 crossrefType "journal-article" @default.
- W2890828211 hasAuthorship W2890828211A5026029965 @default.
- W2890828211 hasAuthorship W2890828211A5039326252 @default.
- W2890828211 hasAuthorship W2890828211A5048644068 @default.
- W2890828211 hasAuthorship W2890828211A5057076335 @default.
- W2890828211 hasAuthorship W2890828211A5058009962 @default.
- W2890828211 hasAuthorship W2890828211A5061742224 @default.
- W2890828211 hasAuthorship W2890828211A5072140037 @default.
- W2890828211 hasAuthorship W2890828211A5080870567 @default.
- W2890828211 hasConcept C100701293 @default.
- W2890828211 hasConcept C126322002 @default.
- W2890828211 hasConcept C143998085 @default.
- W2890828211 hasConcept C170493617 @default.
- W2890828211 hasConcept C192943249 @default.
- W2890828211 hasConcept C203014093 @default.
- W2890828211 hasConcept C2778468042 @default.
- W2890828211 hasConcept C2780851360 @default.
- W2890828211 hasConcept C3020404979 @default.
- W2890828211 hasConcept C3527866 @default.
- W2890828211 hasConcept C502942594 @default.
- W2890828211 hasConcept C59822182 @default.
- W2890828211 hasConcept C71924100 @default.
- W2890828211 hasConcept C86803240 @default.
- W2890828211 hasConcept C88548481 @default.
- W2890828211 hasConcept C8891405 @default.
- W2890828211 hasConceptScore W2890828211C100701293 @default.
- W2890828211 hasConceptScore W2890828211C126322002 @default.
- W2890828211 hasConceptScore W2890828211C143998085 @default.
- W2890828211 hasConceptScore W2890828211C170493617 @default.
- W2890828211 hasConceptScore W2890828211C192943249 @default.
- W2890828211 hasConceptScore W2890828211C203014093 @default.
- W2890828211 hasConceptScore W2890828211C2778468042 @default.
- W2890828211 hasConceptScore W2890828211C2780851360 @default.
- W2890828211 hasConceptScore W2890828211C3020404979 @default.
- W2890828211 hasConceptScore W2890828211C3527866 @default.
- W2890828211 hasConceptScore W2890828211C502942594 @default.
- W2890828211 hasConceptScore W2890828211C59822182 @default.
- W2890828211 hasConceptScore W2890828211C71924100 @default.
- W2890828211 hasConceptScore W2890828211C86803240 @default.
- W2890828211 hasConceptScore W2890828211C88548481 @default.
- W2890828211 hasConceptScore W2890828211C8891405 @default.
- W2890828211 hasLocation W28908282111 @default.
- W2890828211 hasOpenAccess W2890828211 @default.
- W2890828211 hasPrimaryLocation W28908282111 @default.
- W2890828211 hasRelatedWork W2538232731 @default.
- W2890828211 hasRelatedWork W2591318214 @default.
- W2890828211 hasRelatedWork W2797321531 @default.
- W2890828211 hasRelatedWork W2898263433 @default.
- W2890828211 hasRelatedWork W2921402408 @default.
- W2890828211 hasRelatedWork W2947935189 @default.
- W2890828211 hasRelatedWork W2955456037 @default.
- W2890828211 hasRelatedWork W2981400220 @default.
- W2890828211 hasRelatedWork W2982262471 @default.
- W2890828211 hasRelatedWork W3031634650 @default.
- W2890828211 hasRelatedWork W3081744155 @default.
- W2890828211 hasRelatedWork W3118152434 @default.
- W2890828211 hasRelatedWork W3126528925 @default.
- W2890828211 hasRelatedWork W3138626137 @default.
- W2890828211 hasRelatedWork W3172609688 @default.
- W2890828211 hasRelatedWork W3182138840 @default.
- W2890828211 hasRelatedWork W3201169741 @default.
- W2890828211 hasRelatedWork W3203041040 @default.
- W2890828211 hasRelatedWork W3211967314 @default.
- W2890828211 hasRelatedWork W3214579727 @default.
- W2890828211 isParatext "false" @default.
- W2890828211 isRetracted "false" @default.
- W2890828211 magId "2890828211" @default.
- W2890828211 workType "article" @default.